DE69919869D1 - Stimulierung des immunsystems - Google Patents

Stimulierung des immunsystems

Info

Publication number: DE69919869D1
Authority: DE; Germany
Prior art keywords: receptors; stimulation; immune system; inhibitor; immune response
Prior art date: 1998-06-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69919869T

Other languages

English (en)

Other versions

DE69919869T2 (de

Inventor

Karl-Hermann Schlingensiepen

Reimar Schlingensiepen

Wolfgang Brysch

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH

Original Assignee

Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-10

Filing date

1999-06-10

Publication date

2004-10-07

1999-06-10 Application filed by Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH filed Critical Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH

2004-10-07 Application granted granted Critical

2004-10-07 Publication of DE69919869D1 publication Critical patent/DE69919869D1/de

2005-09-29 Publication of DE69919869T2 publication Critical patent/DE69919869T2/de

2019-06-11 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000000987 immune system Anatomy 0.000 title 1
230000000638 stimulation Effects 0.000 title 1
230000028993 immune response Effects 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
102000005962 receptors Human genes 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
102000003814 Interleukin-10 Human genes 0.000 abstract 1
108090000174 Interleukin-10 Proteins 0.000 abstract 1
102000004551 Interleukin-10 Receptors Human genes 0.000 abstract 1
108010017550 Interleukin-10 Receptors Proteins 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 abstract 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
229960002986 dinoprostone Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940076144 interleukin-10 Drugs 0.000 abstract 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Electrotherapy Devices (AREA)

DE69919869T 1998-06-10 1999-06-10 Stimulierung des immunsystems Expired - Lifetime DE69919869T2 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP98110709		1998-06-10
EP98110709		1998-06-10
EP98113974		1998-07-25
EP98113974		1998-07-25
PCT/EP1999/004013 WO1999063975A2 (en)	1998-06-10	1999-06-10	A method for stimulating the immune system

Publications (2)

Publication Number	Publication Date
DE69919869D1 true DE69919869D1 (de)	2004-10-07
DE69919869T2 DE69919869T2 (de)	2005-09-29

Family

ID=26149338

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69919869T Expired - Lifetime DE69919869T2 (de)	1998-06-10	1999-06-10	Stimulierung des immunsystems

Country Status (9)

Country	Link
US (1)	US8629117B2 (de)
EP (1)	EP1089764B1 (de)
JP (1)	JP4627369B2 (de)
AT (1)	ATE274923T1 (de)
AU (1)	AU5154999A (de)
CA (1)	CA2334960C (de)
DE (1)	DE69919869T2 (de)
ES (1)	ES2226414T3 (de)
WO (1)	WO1999063975A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6884787B2 (en)	2001-07-14	2005-04-26	Isis Pharmaceuticals, Inc.	Antisense modulation of transforming growth factor-beta 3 expression
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AU765928B2 (en) *	1999-09-17	2003-10-02	Isis Pharmaceuticals, Inc.	Antisense modulation of transforming growth factor-beta expression
EP1133994A1 (de)	2000-03-11	2001-09-19	Biognostik Gesellschaft für biomolekulare Diagnostik mbH	Verfahren zür Umwandlung des immunosuppresive effekts von MIA (Melanoma Inhibitory Activity)
EP1191097A1 (de) *	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induktion von "exon-skipping" in eukaryotischen Zellen
IL160157A0 (en)	2001-08-17	2004-07-25	Coley Pharm Group Inc	Combination motif immune stimulation oligonucleotides with improved activity
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2006006948A2 (en)	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2213738B1 (de) *	2002-11-14	2012-10-10	Dharmacon, Inc.	siRNA moleküle gegen Bcl-2
CA2502015A1 (en)	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5' cpg nucleic acids and methods of use
EP1444989A1 (de)	2003-02-07	2004-08-11	Giorgio Dr. Stassi	Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
EP2248895B8 (de)	2003-12-19	2016-09-21	Autotelic LLC	Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
JP4871732B2 (ja) *	2003-12-19	2012-02-08	アンティセンスファルマゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物
EP1722823A2 (de) *	2004-02-27	2006-11-22	Antisense Pharma GmbH	Pharmazeutische zusammensetzung
EP1568383A3 (de) *	2004-02-27	2005-11-16	Antisense Pharma GmbH	Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
WO2005110464A2 (en) *	2004-05-14	2005-11-24	Oregon Health & Science University	Irx5 inhibition as treatment for hyperproliferative disorders
BRPI0610499A2 (pt)	2005-04-12	2010-06-22	Intradigm Corp	moléculas de ácido nucléico , composições e usos das referidas moléculas
US7893244B2 (en)	2005-04-12	2011-02-22	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
NZ562954A (en)	2005-05-05	2009-10-30	Antisense Pharma Gmbh	Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors
EP1974740A4 (de) *	2005-10-24	2010-09-01	Proyecto Biomedicina Cima Sl	Verwendung von tgf-beta 1 inhibitor-peptiden bei der herstellung eines mittels zur modulierung der immunantwort
ES2914775T3 (es)	2007-10-26	2022-06-16	Academisch Ziekenhuis Leiden	Medios y métodos para contrarresta trastornos del músculo
USRE48468E1 (en)	2007-10-26	2021-03-16	Biomarin Technologies B.V.	Means and methods for counteracting muscle disorders
EP2119783A1 (de)	2008-05-14	2009-11-18	Prosensa Technologies B.V.	Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
WO2010055148A2 (en) *	2008-11-14	2010-05-20	Antisense Pharma Gmbh	Dosage of oligonucleotides suitable for the treatment of tumors
US8822425B2 (en)	2008-11-14	2014-09-02	Antisense Pharma Gmbh	Dosage of oligonucleotides suitable for the treatment of tumors
CN102712925B (zh) *	2009-07-24	2017-10-27	库尔纳公司	通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
US8936910B2 (en)	2010-06-11	2015-01-20	Antisense Pharma Gmbh	Method for selective oligonucleotide modification
KR20130095737A (ko)	2010-07-28	2013-08-28	알콘 리서치, 리미티드	ＶＥＧＦＡ를 표적으로 하는 ｓｉＲＮＡ 및 생체 내에서 이를 이용한 치료방법
EP2453017A1 (de) *	2010-11-12	2012-05-16	Antisense Pharma GmbH	Oligonucleotide zur Verwendung bei der Prophilaxe und/oder Behandlung von TGF-beta1- und TGF-beta2-, TGF-beta2- und TGF-beta3-, TGF-beta1- und TGF-beta3- oder TGF-beta1-, TGF-beta2- und TGF-beta3-mRNA-Überexpressionskrankheiten
JP2015509922A (ja)	2012-01-27	2015-04-02	プロセンサテクノロジーズビー．ブイ．ＰｒｏｓｅｎｓａＴｅｃｈｎｏｌｏｇｉｅｓＢ．Ｖ．	デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド
WO2017138924A1 (en)	2016-02-09	2017-08-17	Autotelic Llc	Compositions and methods for treating pancreatic cancer
US9758786B2 (en)	2016-02-09	2017-09-12	Autotelic, Llc	Compositions and methods for treating pancreatic cancer
KR102680316B1 (ko) *	2021-11-01	2024-07-01	오토텔릭바이오 주식회사	안티센스 올리고뉴클레오타이드

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2738392A (en)	1991-11-11	1993-05-13	Ciba-Geigy Ag	Novel hybrid transforming growth factors
IL107150A0 (en)	1992-09-29	1993-12-28	Isis Pharmaceuticals Inc	Oligonucleotides having a conserved g4 core sequence
IL108367A0 (en)	1993-01-27	1994-04-12	Hektoen Inst For Medical Resea	Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
DE69432375T2 (de)	1993-04-30	2004-02-12	Biognostik Gesellschaft für Biomolekulare Diagnostik mbH	Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
AU7053894A (en)	1993-06-09	1995-01-03	Ribozyme Pharmaceuticals, Inc.	Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
AU6984594A (en) *	1993-06-15	1995-01-17	Hun Taeg Chung	Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5731294A (en)	1993-07-27	1998-03-24	Hybridon, Inc.	Inhibition of neovasularization using VEGF-specific oligonucleotides
US5772995A (en) *	1994-07-18	1998-06-30	Sidney Kimmel Cancer Center	Compositions and methods for enhanced tumor cell immunity in vivo
US6045802A (en) *	1994-10-03	2000-04-04	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
JP2000509259A (ja)	1996-04-17	2000-07-25	ヘキスト・マリオン・ルセル・ドイチユラント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング	血管内皮増殖因子（ＶＥｇＦ／ＶＰＦ）発現のアンチセンス阻害剤
JPH1052285A (ja)	1996-05-23	1998-02-24	Toagosei Co Ltd	アンチセンス核酸の調製方法
ATE252914T1 (de) *	1996-08-13	2003-11-15	Chiron Corp	Zusammensetzungen zur polynukleotidabgabe
CA2665139A1 (en)	1997-03-07	1998-09-17	Mount Sinai Hospital	Methods to diagnose a required regulation of trophoblast invasion
EP0945507A1 (de)	1998-03-27	1999-09-29	Boehringer Mannheim Gmbh	Tumorspezifische Expressionskontrollregion und deren Verwendung

1999
- 1999-06-10 CA CA2334960A patent/CA2334960C/en not_active Expired - Fee Related
- 1999-06-10 EP EP99936455A patent/EP1089764B1/de not_active Expired - Lifetime
- 1999-06-10 AU AU51549/99A patent/AU5154999A/en not_active Abandoned
- 1999-06-10 DE DE69919869T patent/DE69919869T2/de not_active Expired - Lifetime
- 1999-06-10 JP JP2000553044A patent/JP4627369B2/ja not_active Expired - Fee Related
- 1999-06-10 ES ES99936455T patent/ES2226414T3/es not_active Expired - Lifetime
- 1999-06-10 WO PCT/EP1999/004013 patent/WO1999063975A2/en active IP Right Grant
- 1999-06-10 AT AT99936455T patent/ATE274923T1/de active
2007
- 2007-09-07 US US11/898,080 patent/US8629117B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1089764A2 (de)	2001-04-11
US20080124301A1 (en)	2008-05-29
JP2002517434A (ja)	2002-06-18
DE69919869T2 (de)	2005-09-29
WO1999063975A2 (en)	1999-12-16
ATE274923T1 (de)	2004-09-15
ES2226414T3 (es)	2005-03-16
US8629117B2 (en)	2014-01-14
AU5154999A (en)	1999-12-30
EP1089764B1 (de)	2004-09-01
WO1999063975A3 (en)	2000-08-03
CA2334960A1 (en)	1999-12-16
JP4627369B2 (ja)	2011-02-09
CA2334960C (en)	2012-01-03

Publication	Publication Date	Title
DE69919869D1 (de)	2004-10-07	Stimulierung des immunsystems
FR2679914B1 (fr)	1995-06-23	Composition de caoutchouc de la serie des dienes connjuguees.
DK0817847T4 (da)	2009-10-05	IL-17-receptor
MXPA02001911A (es)	2003-07-21	Anticuerpos ctla-4 humanos y sus usos.
FI962107A7 (fi)	1996-07-16	Imukykyinen tuote, joka sisältää elastista kalvokudosta olevan vyötärönauhan
WO2004017920A3 (en)	2004-07-08	Novel biphenyl and biphenyl-like cannabinoids
NL1003300A1 (nl)	1996-12-10	Implanteerbare therapeutische inrichting.
CY1106234T1 (el)	2011-06-08	Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
NZ312327A (en)	2000-01-28	Controlling hemipteran insect pests with bacillus thuringiensis
FR2805465B1 (fr)	2003-02-21	Nouvelles compositions pharmaceutique ou dietetiques a base de champignons
DE50004334D1 (de)	2003-12-11	Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
GR1002768B (el)	1997-09-23	Δηλητηριασμενα δολωματα για τον ελεγχο των επιβλαβων εντομων.
ES2164914T3 (es)	2002-03-01	Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
PT932613E (pt)	2005-06-30	Expressao de bloqueio de factoes de virulencia em s. aureus
DE69841260D1 (de)	2009-12-10	Bakterielle pheromone und deren verwendungen
IT9048066A0 (it)	1990-06-15	2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
ATE255594T1 (de)	2003-12-15	Hepatitis b inhibitoren
BR0009221A (pt)	2001-12-26	Vetores virais de inseto e usos dos mesmos
ITRM960096V0 (it)	1996-05-17	Dispositivo per il trattamento del corpo umano.
RU96115480A (ru)	1998-10-27	Лекарственное средство, обладающее холелитолитическим действием
FR2708855B1 (fr)	1995-10-13	Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
EP0729950A4 (de)	2001-02-07	Anti-hiv arzneimittel
IT239134Y1 (it)	2001-02-19	Dispositivo aspirante, particolarmente per w.c.
UA33424A (uk)	2001-02-15	Пристрій для профілактики та лікування постмастектомічного синдрому
IT241458Y1 (it)	2001-05-09	Protezione degli arti del cavallo.

Legal Events

Date	Code	Title	Description
2005-11-03	8364	No opposition during term of opposition